Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 1;64(9):1268-1270.
doi: 10.1093/cid/ciw864.

Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System

Lao-Tzu Allan-Blitz  1 , Romney M Humphries  2 , Peera Hemarajata  2 , Ashima Bhatti  3 , Mark W Pandori  4 , Mark J Siedner  5 , Jeffrey D Klausner  6   7
Affiliations

Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System

Lao-Tzu Allan-Blitz et al. Clin Infect Dis. .

Abstract

Multidrug-resistant Neisseria gonorrhoeae is a top threat to public health. In November 2015, UCLA Health introduced a rapid gyrase A (gyrA) genotypic assay for prediction of Neisseria gonorrhoeae susceptibility to ciprofloxacin. We found a significant reduction in ceftriaxone use with a concomitant increase in targeted therapy.

Keywords: Neisseria gonorrhoeae; antibiotic resistance.; ciprofloxacin; gyrA.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percent of non-empirically treated gyrA wild-type Neisseria gonorrhoeae cases treated with ciprofloxacin at UCLA Health between 1 January 2015 and 29 July 2016. Period 1 is the period before assay implementation (1 January 2015 – 31 October 2015), during which time there were no genotype results available. Period 2 is the initial seven months of assay implementation prior to sending electronic reminders of genotype results to providers (1 November 2015 – 26 May 2016). Period 3 is the final two months of assay implementation after electronic reminder notifications began (27 May 2016– 29 July 2016). *Electronic reminders began 27 May 2016
See this image and copyright information in PMC

References

    1. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 2014; 27:587–613. - PMC - PubMed
    1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 2015; 40:277–83. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC, 2013.
    1. Siedner MJ, Pandori M, Castro L, et al. Real-time PCR assay for detection of quinolone-resistant Neisseria gonorrhoeae in urine samples. J Clin Microbiol 2007; 45:1250–4. - PMC - PubMed
    1. Allan-Blitz L, Klausner JD. Neisseria gonorrhoeae susceptibility to ciprofloxacin. MLO Med Lab Obs 2016; 48:30. - PubMed

MeSH terms